Modified-Release Mechanism of Reclide MR (Gliclazide MR)
Reclide MR (gliclazide modified release) utilizes a hydrophilic matrix system composed of hypromellose-based polymer that induces progressive drug release over 24 hours, paralleling the natural glycemic profile in type 2 diabetic patients and enabling once-daily dosing. 1, 2
How the Technology Works
The modified-release formulation employs a specifically designed hydrophilic matrix that controls drug release through a combination of mechanisms:
- Progressive dissolution: The hypromellose polymer matrix swells upon contact with gastrointestinal fluids, creating a gel layer that controls the rate of drug diffusion 1, 2
- Erosion and diffusion: Drug release occurs through both erosion of the outer gel layer and diffusion through the hydrated matrix 3
- 24-hour release profile: This results in sustained plasma concentrations that match the diurnal glycemic fluctuations in diabetic patients 1
Clinical Advantages of the MR Formulation
Complete bioavailability: The formulation achieves 97% absolute bioavailability (range 79-110%), demonstrating complete absorption of gliclazide 4
Food-independent absorption: Unlike many medications, gliclazide MR can be taken before, during, or after meals without affecting its pharmacokinetic profile—no significant differences occur in Tmax, t½, Cmax, or AUC under fasted versus fed conditions 4
Low pharmacokinetic variability: The consistent release pattern results in moderate-to-low variability in plasma concentrations, making the drug's effects more predictable 4
Dosing Implications
The MR formulation allows for:
- Once-daily administration (compared to twice-daily dosing with immediate-release gliclazide) 5, 2
- Flexible timing: Can be taken at any time relative to meals 4
- Lower total daily dose: Gliclazide MR 30-120 mg once daily achieves similar efficacy to immediate-release gliclazide 80-320 mg/day in divided doses 2
Safety Profile Related to MR Technology
The sustained-release mechanism contributes to improved safety:
- Reduced hypoglycemia risk: The gradual release avoids peak plasma concentrations that could trigger hypoglycemic episodes 6
- No nocturnal hypoglycemia: Studies showed no episodes of nocturnal hypoglycemia with the MR formulation 2
- Weight neutral: Body weight remains stable during treatment 2
Practical Considerations
During Ramadan fasting: The once-daily MR formulation is particularly advantageous—the dose should be taken at the sunset meal (Iftar) when fasting 6, 7. This timing flexibility is enabled by the 24-hour release profile.
Patient compliance: Once-daily dosing significantly improves adherence compared to multiple daily doses, which is crucial for long-term glycemic control 5
The modified-release technology represents a pharmaceutical advancement that optimizes the pharmacokinetic profile of gliclazide while maintaining its established efficacy and improving its safety and convenience profile.